利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.015 秒)

    ENHANCED FIRST GENERATION ADENOVIRUS VACCINES EXPRESSING CODON OPTIMIZED HIV1-GAG, POL, NEF AND MODIFICATIONS
    4.
    发明公开
    ENHANCED FIRST GENERATION ADENOVIRUS VACCINES EXPRESSING CODON OPTIMIZED HIV1-GAG, POL, NEF AND MODIFICATIONS 审中-公开
    改进的疫苗腺病毒表达的第一代密码子优化的HIV-1 GAG，POL，NEF和修饰（02年3月25日）

    公开(公告)号：EP1320621A2

    公开(公告)日：2003-06-25

    申请号：EP01975214.6

    申请日：2001-09-14

    申请人： Merck & Co., Inc.

    发明人： EMINI, Emilio, A. ,  YOUIL, Rima ,  BETT, Andrew, J. ,  CHEN, Ling ,  KASLOW, David, C. ,  SHIVER, John, W. ,  TONER, Timothy, J. ,  CASIMIRO, Daniel, R.

    IPC分类号： C12N15/86

    CPC分类号： C12N7/00 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/57 ,  C07K14/005 ,  C12N15/86 ,  C12N2710/10343 ,  C12N2710/10351 ,  C12N2740/16134 ,  C12N2740/16334 ,  C12N2830/42

    摘要： First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV1- Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, encoding codon optimized HIV-1 Pol, derivatives of optimized HIV-1 Pol (including constructs wherein protease, reverse transcriptase, RNAse H and integrase activity of HIV-1 Pol is inactivated), HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef mutants which effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4. The adenoviral vaccines of the present invention, when administered alone or in a combined modality regime, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.

    ADENOVIRAL VECTOR COMPOSITIONS
    6.
    发明公开
    ADENOVIRAL VECTOR COMPOSITIONS 审中-公开
    腺病毒载体组合物

    公开(公告)号：EP1786904A2

    公开(公告)日：2007-05-23

    申请号：EP05779520.5

    申请日：2005-08-05

    申请人： Merck & Co., Inc.

    发明人： EMINI, Emilio, A. ,  SHIVER, John, W. ,  CASIMIRO, Danilo, R. ,  BETT, Andrew, J.

    IPC分类号： C12N15/00 ,  C12N7/00 ,  A61K49/00 ,  A61K39/12

    CPC分类号： C12N15/86 ,  A61K39/12 ,  A61K39/21 ,  A61K48/00 ,  A61K48/0083 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/57 ,  C07K14/005 ,  C12N7/00 ,  C12N2710/10343 ,  C12N2740/16134 ,  C12N2740/16334

    摘要： Applicants disclose herein novel methods, vectors, and vector compositions for improving the efficiency of adenoviral vectors in the delivery and expression of heterologous nucleic acid encoding a polypeptide(s) (e.g, a protein or antigen) of interest. Adenoviral infection is quite common in the general population, and a large percentage of people have neutralizing antibodies to the more prevalent adenoviral serotypes. Such pre-existing anti-adenoviral immunity can dampen or possibly abrogate the effectiveness of this virus for the delivery and expression of heterologous proteins or antigens. The method taught herein functions to offset pre-existing immunity through the delivery of the protein or antigen by a cocktail of at least two adenoviral serotypes. Utilizing a composition of at least two adenoviral serotypes in this manner has been found to increase the effectiveness of adenoviral administration. Adenoviral vectors of utility in the elicitation of an immune response against Human Immunodeficiency Virus ("HIV") are also disclosed.

    HIV PROTEASE INHIBITOR COMBINATION
    9.
    发明授权
    HIV PROTEASE INHIBITOR COMBINATION 失效
    HIV蛋白酶抑制剂组合

    公开(公告)号：EP0774969B1

    公开(公告)日：2003-02-19

    申请号：EP95930118.5

    申请日：1995-08-07

    申请人： Merck & Co., Inc.

    发明人： DEUTSCH, Paul, J. ,  EMINI, Emilio, A. ,  VACCA, Joseph, P.

    IPC分类号： A61K31/495 ,  A61K31/435 ,  A61K31/425

    CPC分类号： A61K31/496 ,  A61K31/4709 ,  A61K31/435 ,  A61K31/427 ,  A61K2300/00

    摘要： The combination of the HIV protease inhibitor Compound J and any one or more of four other potent HIV protease inhibitors is useful in the inhibition of HIV protease, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

    摘要翻译： HIV蛋白酶抑制剂化合物J与四种其他强效HIV蛋白酶抑制剂中的任何一种或多种的组合可用于抑制HIV蛋白酶，预防或治疗HIV感染和治疗AIDS，作为化合物，药学上可接受的 盐，药物组合物成分，不论是否与其他抗病毒剂组合，免疫调节剂，抗生素或疫苗。 还描述了治疗AIDS的方法和预防或治疗HIV感染的方法。